HCPCS code J3488: Zoledronic acid (Reclast) billing guide

Key takeaways

HCPCS code J3488 (injection, zoledronic acid [Reclast], 1 mg) is deleted and cannot be used for claim submission.

J3489 replaced it and covers zoledronic acid 1 mg from any brand, including Reclast and Zometa.

J3487 and the interim code Q2051 also died on January 1, 2014, so older charge masters often hold more than one dead entry.

Reclast is billed as 5 units of J3489 for a 5 mg dose, and Zometa as 4 units for 4 mg.

Pabau’s claims management software pre-fills the claim from the record and provides ICD-10, CPT and HCPCS lookup libraries.

HCPCS code J3488 is a deleted Level II code that once described injection, zoledronic acid (Reclast), 1 mg. It has not been payable since January 1, 2014.

Legacy charge masters and older superbill templates keep J3488 alive long after it stopped being payable. The rejection then arrives before anyone notices the code.

The rest of this page handles the crosswalk, the unit math, and the documentation Medicare wants before it pays.

What HCPCS code J3488 covered before CMS deleted it

HCPCS code J3488 described “Injection, zoledronic acid (Reclast), 1 mg.” The Centers for Medicare and Medicaid Services (CMS) assigned it as a Level II J-code. It identified intravenous zoledronic acid supplied under the Reclast brand.

The code was billed per 1 mg administered, so a standard 5 mg infusion carried 5 units.

While J3488 was active, the descriptor named Reclast explicitly. That mattered because the same molecule is also sold as Zometa for oncology indications, and Zometa carried its own code.

J3489 dropped the brand restriction entirely. Any claim submitted with J3488 today will be rejected. Before your next billing cycle, check every J-code in the charge master against the current HCPCS code list.

Three zoledronic acid codes died on the same date

J3488 was not retired on its own. CMS collapsed the brand-specific family into a single generic code, and the transition ran through a short-lived interim code in between.

That is why an old drug file can carry more than one dead zoledronic acid entry.

Turn that into a charge-master audit. If your drug file predates 2014, search it for J3487 and Q2051 as well as J3488. The deleted-code record for J3488 confirms the January 1, 2014 date.

All three are dead. Only J3489 pays, and it covers Reclast, Zometa and generic zoledronic acid alike.

J3489 replaced J3488, and the unit count is where claims fail

J3489 is the current, active code for zoledronic acid infusions. Its descriptor reads “Injection, zoledronic acid, 1 mg,” with no brand named. That single descriptor covers Reclast at 5 mg/100 mL and Zometa at 4 mg/5 mL.

The dose difference between the two brands is the largest single source of error on crosswalk claims. Reclast is dispensed as a 5 mg/100 mL infusion, so you bill 5 units of J3489.

Zometa is dispensed as 4 mg/5 mL, so you bill 4 units. Read the milligrams off the administration record every time, rather than copying the unit count from the last claim.

Reclast and Zometa are the same molecule at different doses

Zoledronic acid is a third-generation intravenous bisphosphonate. It inhibits osteoclast-mediated bone resorption, which makes it useful wherever excessive bone turnover drives the disease.

The FDA has approved two branded formulations with different indications, and both bill under the same drug code.

• Reclast, 5 mg/100 mL: approved for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. Given as a single annual or biennial infusion over at least 15 minutes.
• Zometa, 4 mg/5 mL: approved for hypercalcemia of malignancy, multiple myeloma, and bone metastases from solid tumors. Infusion duration is at least 15 minutes.
• Generic zoledronic acid: also billed under J3489, provided the NDC on the claim matches the product administered.

The National Drug Code, or NDC, has to appear on the claim alongside J3489. Medicare uses it to cross-reference the drug dispensed against the units billed.

Capture the NDC and the lot number at the point of care. Rebuilding them from a pharmacy invoice later rarely matches what went into the patient.

Coverage follows the indication, not the brand you infused

Medical necessity for a zoledronic acid infusion rests on the diagnosis, not on which bottle you opened. The indication has to be FDA-approved and covered under CMS Local Coverage Determination (LCD) L33270, which governs intravenous bisphosphonates and monoclonal antibodies.

A correct J3489 with an uncovered diagnosis is still a medical necessity denial.

Medicare does not cover off-label use of zoledronic acid under this LCD. Document the approved indication in the record before the infusion is ordered.

Where a patient carries several conditions, link the claim to the diagnosis that drove this particular encounter.

These ICD-10 codes carry medical necessity for J3489

Every zoledronic acid claim needs at least one ICD-10-CM code that maps to a covered indication under LCD L33270. Covered code lists change with each fiscal year.

Check them against the CMS ICD-10 codes page every year, not against a list saved in a shared drive.

Use the most specific code the record supports. Code osteoporosis to the site when a pathological fracture is present, using the M80 series.

For Paget disease, code to the affected bone where the note documents it. Unspecified codes still pay, but they draw audits more often, so avoid reaching for them out of habit.

CPT 96365 pays for the infusion, J3489 pays for the drug

Billing J3489 on its own leaves the infusion service unpaid. The drug code and the administration code are separate line items, and both belong on the claim.

Administration is reported with the time-based CPT codes in the 96360 to 96379 range.

• CPT 96365: initial intravenous infusion, up to 1 hour. This is the primary administration code for a standard zoledronic acid infusion. Reclast runs a minimum of 15 minutes, and most encounters finish well inside the hour.
• CPT 96366: each additional hour of intravenous infusion, reported as an add-on to 96365. Use it only when infusion time runs past 60 minutes.
• Place of service: administration is billable in physician offices, POS 11, and hospital outpatient settings, POS 22. Medicare pays each setting at a different rate.

Infusion start and stop times have to appear in the clinical note. A note that says only “infusion given” will not support the administration code when a reviewer asks.

Practices billing from an office setting should also confirm the place of service code matches where the infusion took place.

What Medicare Part B needs before it pays

Medicare Part B covers zoledronic acid infusions given in a physician office or an outpatient setting. Coverage runs under LCD L33270, as maintained by your Medicare Administrative Contractor (MAC).

The CMS LCD L33270 code guide lists the covered HCPCS codes, the covered diagnosis codes, and the documentation each indication requires.

Four requirements decide most of these claims:

• Diagnosis confirmation: the record documents the covered indication with supporting findings, such as DEXA results, serum calcium, or a pathology report.
• Frequency limits: Reclast for osteoporosis is generally covered once a year. Zometa in oncology follows the treating oncologist’s documented plan. An infusion outside those limits needs supporting documentation.
• Prior authorization: Part B generally does not require it for covered bisphosphonate infusions in an office setting. Commercial payers vary, so verify before you schedule.
• NDC on the claim: the 11-digit NDC has to accompany J3489 so Medicare can cross-reference the drug dispensed.

Checking eligibility and benefits before the appointment is what stops most of these denials. The drug is expensive, and a coverage problem found after the infusion leaves the practice holding the cost.

Six steps that get a zoledronic acid claim paid

A payable claim needs the code, the units, the diagnosis and the administration code all correct, and a single miss sends it back.

The six steps below are the order a billing team works in:

1. Confirm the drug and dose administered. Reclast 5 mg bills as 5 units of J3489. Zometa 4 mg bills as 4 units. Generic zoledronic acid bills at one unit per milligram.
2. Select the ICD-10-CM code. Use the most specific option the record supports, then confirm it sits on your MAC’s covered list for LCD L33270.
3. Add CPT 96365 for the administration service. Bring in 96366 only when documented infusion time runs past 60 minutes.
4. Include the NDC. It goes on the claim in the 5-4-2 digit format with the N4 qualifier, on CMS-1500 line 24D or in the 837P file.
5. Check the place of service code against where the infusion happened. POS 11 covers a physician office, POS 22 hospital outpatient.
6. Submit J3489, never J3488. Scan the charge master and superbill templates for legacy entries before each billing cycle.

How one annual Reclast infusion is coded

A 68-year-old patient with age-related osteoporosis arrives for her annual Reclast infusion. The pharmacy supplies one 5 mg/100 mL bottle. The nurse records a start time of 10:14 and a stop time of 10:37.

That encounter produces five claim entries:

• J3489 with a unit count of 5, matching the 5 mg administered
• The NDC printed on that bottle, carried with the N4 qualifier
• M81.0, age-related osteoporosis without current pathological fracture
• CPT 96365 for the initial intravenous infusion, up to 1 hour
• POS 11, because the infusion happened in the physician office

The infusion ran 23 minutes, so CPT 96366 has no place on this claim. Swap the bottle for a 4 mg Zometa vial and only two entries change. The unit count drops to 4, and the diagnosis moves to the oncology indication on file.

The five-second check before you hit submit

• Units equal the milligrams on the administration record, not the milligrams in the box
• The diagnosis code appears on your MAC’s covered list for LCD L33270
• CPT 96365 is on the claim, with start and stop times in the note
• The NDC matches the bottle the nurse opened
• The drug code reads J3489, not J3488, J3487 or Q2051

Those five checks head off the errors in the table below.

Seven errors that stall zoledronic acid claims

Zoledronic acid claims fail in a small number of predictable ways. The table pairs each error with what the payer does about it, then the fix that stops it recurring.

One denial reason repeating across several zoledronic acid claims points at a workflow problem rather than a coding slip.

Track the reasons monthly, and check code status against the CMS HCPCS overview whenever an annual update lands.

How Pabau moves an infusion claim from the record to the payer

In most infusion practices the drug, the dose, the diagnosis and the times sit in the clinical note. Someone retypes them into a claim form later that week. That retyping is where the unit count drifts and the NDC goes missing.

Practice management software like Pabau builds the claim from the record instead. The codes already attached to the service land on the charge line, and the ICD-10 slots are seeded from the client’s recorded problem list.

Search icons open full ICD-10-CM and CPT/HCPCS lookup libraries, refreshed with each official release, so a coder can confirm J3489 without leaving the form.

The last check is completeness. Pabau is built for claims that leave complete, so the Send button stays locked until required fields like membership and authorization numbers are filled.

Submission then runs through the clearinghouse for your region, which in the US is Claim.MD. That pipeline also returns real-time eligibility checks, claim-status tracking, and electronic remittance posting.

None of that picks the code for you. It removes the retyping step where units and NDCs get lost. The coder then spends their time on judgment calls instead of data entry.

Build infusion claims straight from the record

Pabau pre-fills the claim from the clinical record and opens full ICD-10 and HCPCS lookup libraries at the charge line. Submission waits until the required fields are complete, then goes out through your region’s clearinghouse.

Book a demo

Conclusion

J3488 has not paid since January 1, 2014, and neither has J3487 or Q2051. Delete all three from your drug file and the rejections stop arriving.

Once J3489 is the only zoledronic acid code in the system, the remaining risk moves to the unit count. Reclast and Zometa look identical on a charge line and differ by one unit. The check that matters is the milligram figure on the administration record, and it belongs in the workflow rather than in someone’s memory.

The workflow worth building is simple. The record produces the claim, required fields are checked before it goes out, and the clearinghouse takes it from there.

Book a demo to see how Pabau moves an infusion claim from the treatment note to your payer without a retyping step.

Continue your research

Need the code that pays today? J3489 covers the descriptor, the unit counts and the coverage rules for the active zoledronic acid code.

Billing the infusion service as well as the drug? CPT 96365 covers the time thresholds, the add-on rules and the documentation an administration code needs.

Coding an osteoporosis infusion? M81.0 covers when age-related osteoporosis without current pathological fracture is the diagnosis to submit.

Want a checklist for a first-pass claim? Clean claim requirements sets out the elements payers validate before they process a drug or infusion claim.

Seeing the same denial reason repeat? Denial management in healthcare covers how to identify, appeal and prevent recurring claim denials.

Frequently asked questions